John Simard is CEO at XBiotech Inc. (XBIT). They have made 8 open-market trades across 1 company since 2021, most recently 2026-10-26.
CIK 0001639078
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $711K since 2024, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XBIT | 4,191,690 | $8.2M |
Shares reported on the most recent Form 4, priced at the 2026-10-28 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XBIT | BUY | 2026-10-26 | 2026-10-28 | $1.93 | $711K | — | — | — |
| XBIT | SELL | 2021-10-15 | 2022-02-15 | $13.16 | $658K | -3.6% | -6.1% | -45.5% |
| XBIT | SELL | 2021-10-07 | 2021-10-15 | $12.66 | $2.0M | +7.1% | +2.6% | -13.9% |
| XBIT | SELL | 2021-10-04 | 2021-10-06 | $12.84 | $1.2M | +4.0% | +27.4% | -9.9% |
| XBIT | SELL | 2021-09-28 | 2021-10-01 | $13.34 | $1.6M | -0.6% | +17.9% | -13.8% |
| XBIT | SELL | 2021-09-23 | 2021-09-28 | $14.71 | $1.5M | -7.6% | +2.3% | -20.8% |
| XBIT | SELL | 2021-09-20 | 2021-09-22 | $15.15 | $1.5M | -13.4% | -6.1% | -24.7% |
| XBIT | SELL | 2021-07-14 | 2021-07-19 | $18.15 | $1.8M | +4.1% | +0.1% | -16.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.